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Abstract: Local accumulation of Advanced Oxidation Protein Products (AOPP) induces
pro-inflammatory and pro-fibrotic processes in kidneys and is an independent predictor of renal
fibrosis and of rapid decline of eGFR in patients with chronic kidney disease (CKD). In addition
to kidney damage, circulating AOPP may be regarded as mediators of systemic oxidative stress
and, in this capacity, they might play a role in the progression of atherosclerotic damage
of arterial walls. Atherosclerosis is a chronic inflammatory disease that involves activation of
innate and adaptive immunity. Dendritic cells (DCs) are key cells in this process, due to their
role in antigen presentation, inflammation resolution and T cell activation. AOPP consist in
oxidative modifications of proteins (such as albumin and fibrinogen) that mainly occur through
myeloperoxidase (MPO)-derived hypochlorite (HOCl). HOCl modified proteins have been found
in atherosclerotic lesions. The oxidizing environment and the shifts in cellular redox equilibrium
trigger inflammation, activate immune cells and induce immune responses. Thus, surface thiol
groups contribute to the regulation of immune functions. The aims of this work are: (1) to evaluate
whether AOPP-proteins induce activation and differentiation of mature macrophages into dendritic
cells in vitro; and (2) to define the role of cell surface thiol groups and of free radicals in this process.
AOPP-proteins were prepared by in vitro incubation of human serum albumin (HSA) with HOCl.
Mouse macrophage-like RAW264.7 were treated with various concentrations of AOPP-HSA with or
without the antioxidant N-acetyl cysteine (NAC). Following 48 h of HSA-AOPP treatment, RAW264.7
morphological changes were evaluated by microscopic observation, while markers of dendritic
lineage and activation (CD40, CD86, and MHC class II) and allogeneic T cell proliferation were
evaluated by flow cytometry. Cell surface thiols were measured by AlexaFluor-maleimide binding,
and ROS production was assessed as DCF fluorescence by flow cytometry. HSA-AOPP induced
the differentiation of RAW264.7 cells into a dendritic-like phenotype, as shown by morphological
changes, by increased CD40, CD86 and MHC class II surface expression and by induction of T cell
proliferation. The cell surface thiols dose dependently decreased following HSA-AOPP treatment,
while ROS production increased. NAC pre-treatment enhanced the amount of cell surface thiols
and prevented their reduction due to treatment with AOPP. Both ROS production and RAW264.7
differentiation into DC-like cells induced by HSA-AOPP were reduced by NAC. Our results highlight
that oxidized plasma proteins modulate specific immune responses of macrophages through a process
involving changes in the thiol redox equilibrium. We suggest that this mechanism may play a role in
determining the rapid progression of the atherosclerotic process observed in CKD patients.
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1. Introduction
Advanced Oxidation Protein Products (AOPP) are oxidative stress biomarkers that are initially
found at high levels in the plasma of patients with chronic kidney disease (CKD). Furthermore, it was
shown that AOPP correlate with creatinine clearance and, since then, they have been considered a
marker of renal damage progression [1]. AOPP include oxidative modifications of proteins that mainly
occur through myeloperoxidase (MPO)-derived hypochlorite (HOCl) production [2].
AOPP concentrations were found to be the highest in hemodialysis patients followed by patients
on peritoneal dialysis. Similarly, AOPP levels in non-dialyzed pre-terminal renal failure patients were
also increased as compared to healthy controls, which led to AOPP being included in the family of
uremic toxins. Moreover, the ability to activate phagocytes and to induce production of cytokines such
as interleukin-6 (IL6), tumor necrosis factor alpha (TNF), and interleukin-1beta (IL1b) suggests that
AOPP act as pro-inflammatory mediators [3,4].
Besides their role in the progression of uremia, AOPP are involved as mediators of systemic
oxidative stress and of inflammatory processes in several clinical conditions such as diabetes mellitus
and its renal complications, systemic sclerosis and coronary artery disease [5–8].
AOPP have been linked to progression of atherosclerosis and to the occurrence of cardiovascular
events [9] as is also observed with other protein-bound uremic toxins [10].
Both the generation of free radicals in cells and the inflammatory response induced by AOPP are
important drivers of the progression of atherosclerosis and as triggers of cardiovascular disease (CVD)
events. As plasma protein bound moieties, AOPP act at the circulating level as well as on resident
cells. The interaction and effect on innate immune cells, such as neutrophils, monocytes, macrophages
and dendritic cells (DCs) have come under careful scrutiny. It has been demonstrated that immune
cells, such as monocytes and neutrophils are activated by AOPP. AOPP induce oxidative bursts in
monocytes and in neutrophils in vitro. Oxygenation activities of NADPH oxidase and Myeloperoxidase
in polymorphonuclear cells and monocytes increased in vitro in a dose-dependent manner following
treatment with human serum albumin (HSA)-AOPP [11,12]. Recruitment of mononuclear phagocytes
occurs during inflammatory processes and gives rise to differentiated cells including inflammatory
DCs with different functions such as antigen presentation to effector T cells. Thus, DCs in secondary
lymphoid organs work toward the induction and maintenance of systemic immunity. However, due to
their plasticity, monocytes, macrophages and DCs surface markers and functions largely overlap,
and, moreover, an excessive reaction to systemic antigens may spread responses therefore potentially
damaging arterial vessel walls and body tissues [13,14].
Besides residing in lymphoid organs, DCs are present in most peripheral tissues in the body
and are activated by inflammatory signals. In turn, they activate T cells, thus providing a bridge
between innate and adaptive immunity. The main activity of DCs consists in the presentation of
antigens to T cells in the periphery, thereby contributing to protection against pathogens. This pathway
becomes overstimulated in chronic pro-inflammatory conditions, and, in this case, in addition to
linking adaptive and innate immunity, DCs also act in an antigen-independent fashion, thus bypassing
protective immunity and promoting tissue fibrosis, as occurs in advanced renal diseases [15–17].
Redox status has recently been implicated in cell signaling, and post-translational modifications
of proteins may participate in gene expression control and metabolism regulation. An oxidizing
environment may act as an activator of both circulating and resident immune cells. The redox
equilibrium and a non-oxidizing environment are key factors in maintaining protective (functional) cell
immunity: disturbances in this homeostatic mechanism may trigger altered inflammatory and immune
responses. Albumin is considered the main antioxidant molecule in plasma due to its abundance in
thiol groups [18]. Thiol groups participate in cellular redox homeostasis and contribute to regulating
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immune functions. There is evidence that AOPP are oxidative stress biomarkers, but that they are also
circulating moieties that affect leukocytes. Moreover, hypochlorite-modified proteins have been found
in atherosclerotic lesions. The aim of this work is to evaluate whether AOPP-protein might induce the
differentiation of mature macrophages into DCs and whether cell surface thiol groups are involved in
this process. The efficacy of the N-acetyl cysteine (NAC) antioxidant in modulating these processes
has also been tested.
2. Results
2.1. AOPP Induced Morphologic Changes in RAW264.7 Cells toward DC-Like Cells
RAW264.7 cells differentiated from a macrophage-like appearance into a dendritic-like aspect
following 48 h of incubation with increasing concentrations of HSA-AOPP, as shown by morphological
changes assessed by microscopic observation (Figure 1A). Cell count indicated that HSA-AOPP
significantly increased the percentage of cells having dendritic morphology (Figure 1B). Native HSA
did not induce clear-cut morphological changes. Microscopic evaluation of cells showing dendritic
phenotype was consistent with cytometry-assessed morphological parameters. Flow cytometric
analysis of the forward scatter (FSC), reflecting the cell size, was not significantly altered by AOPP,
while the side scatter (SSC), which indicates cell complexity, increased after AOPP treatment (Figure 1C).
At the highest AOPP concentration, the increase in the median SSC cell morphology parameter lacked
statistical significance over native HSA. We believe that this may be due to an increase in the SSC
induced by the corresponding native HSA concentration against which statistical comparison has been
performed, and/or to the appearance of a low but significant degree of apoptosis (highlighted in the
hypodiploid DNA data presented in Section 2.4).Toxins 2017, 9, 27    4 of 18 
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treatment, a transient increase was observed at 24 h, that rapidly dropped to near basal levels at the 
48‐hour interval (Figure 2B). The surface expression of DC markers CD40, MHC Class II and CD86 
increased at 24 h and  continued  to  increase up  to 48 h  (Figure 2C–E). These  results  suggest  that 
oxidized  albumin  uptake  by  CD36  may  represent  a  first  step  leading  to  the  process  of  DC 
differentiation. 
Figure 1. (A) Phase contrast microscopy of AW cells cultured with different HSA-AOPP
concentrations (magnification 100×); (B) Percentage count of RAW cells observed by phase contrast
microscopy. Data r pr sent mean + SE. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. untreated cells; (C) Flow
cytometric evaluation of RAW cell complexity as a percentage of Mean Fluorescence Intensity (MFI) of
side scatter (SSC-H). Data represent mean + SE. * p < 0.05 vs. native HSA.
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2.2. CD36 Expression in RAW264.7 Cells and Time Course of Surface DC Markers upon Treatment
with HSA-AOPP
RAW264.7 cells have the features of a macrophage cell line, and show high expression of CD36,
a key receptor that is responsible for the uptake of modified low density lipoproteins leading to
lipid loading in macrophages and which is an important factor resulting in endoplasmic reticulum
(ER) stress [19]. CD36 surface expression did not increase following 48 h of HSA-AOPP treatment
(Figure 2A). However, by analyzing the time course of CD36 surface expression following HSA-AOPP
treatment, a transient increase was observed at 24 h, that rapidly dropped to near basal levels at the
48-hour interval (Figure 2B). The surface expression of DC markers CD40, MHC Class II and CD86
increased at 24 h and continued to increase up to 48 h (Figure 2C–E). These results suggest that oxidized
albumin uptake by CD36 may represent a first step leading to the process of DC differentiation.
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Figure 2. CD36 expression in RAW264.7 cells: (A) CD36 analysis of RAW cells treated with HSA-AOPP
and with native-HSA; and (B–E) time course surface expression of CD36, CD40, MHC Class II,
and CD86, respectively, in RAW cells treated with HSA-AOPP.
2.3. HSA-AOPP Induced Phenotypic DC Markers Expression in RAW264.7 Cells. Flow Cytometry of
Phenotypic Parameters
Following a 48 h treatment with HSA-AOPP, RAW264.7 macrophages showed an increased
expression of markers, thus refl cting commitment to dendritic cell lineage and activation. As shown
in Figure 3, HSA-AOPP dose-dependently increased he surface expression of CD40, wh se signaling
gives rise to upregulation of MHC class II and of co-stimulatory molecule CD86, which are, respectively,
markers of DC maturation and activation, thereby re ering the effective antig n-presenting
cells [20].
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Figure 3. Phenotype analysis, assessed by the DC markers CD40 (a); MHC Class II (b) and CD86 (c),
of RAW cells treated with HSA-AOPP and with native-HSA. * p < 0.05, ** p < 0.01 vs. native-HSA.
2.4. Evaluation of Cell Viability
Hypodiploid DNA was evaluated as an index of cell apoptosis. RAW264.7 were treated with
a wide range of concentrations of HSA-AOPP though maintaining a sub-toxic level. AOPP-HSA
had very little effect on cell viability, even after 48 h of treatment. The apoptotic index as mirrored
by hypodiploid DNA evaluation was significantly higher than the levels observed in native-HSA
treatment, albeit only at the highest amount that was used (Figure 4A). Even at that concentration,
however, the hypodiploid DNA fraction was minimal as compared to living nuclei, suggesting that
most cells remained alive and responsive to treatment in terms of both phenotypic and functional DC
features. We also evaluated apoptosis using Annexin V and Propidium Iodide (PI) staining. The results
reported in Figure 4B do not show any significant increase in either Annexin V positive/PI negative
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surface  thiol  pool,  as  shown  by  AlexaFluor maleimide  fluorescence  decrease. On  the  contrary, 
changing concentrations of native HSA had no effect on the surface thiol pool (Figure 5A). Similarly, 





Figure 4. (A) Hypodiploid DNA evaluation in RAW264.7 cells treated with HSA-AOPP or native-HSA;
and (B) flow cytometric Annexin V and Propidium Iodide assay; * p < 0.05 vs. native-HSA.
2.5. Cell Surface Thiol Groups and Intracellular ROS Production Are Modulated by HSA-AOPP
HSA-AOPP treatment of RAW264.7 cells for 2 h induced a dose-dependent decrease of the
cell surface thiol pool, as shown by AlexaFluor maleimide fluorescence decrease. On the contrary,
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changing concentrations of native HSA had no effect on the surface thiol pool (Figure 5A). Similarly,
as compared to native HSA, HSA-AOPP induced an increase in intracellular ROS production in
RAW264.7 cells evaluated by dichlorofluorescein fluorescence after a 30-min treatment (Figure 5B).
Data from Figure 5A,B suggest that there is likely an association between the decrease in cell surface
thiols and the increase in intracellular ROS production. An analysis of the correlation resulted in a
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Figure 5. (A) Cell surface thiols in cells treated with HSA-AOPP and with native HSA. * p < 0.05
vs. HSA-native; (B) ROS production in RAW264.7 cells. * p < 0.05 vs. untreated control cells and
vs. HSA-native 10 nmol/mL; *** p < 0.001 vs. untreated control cells; § p < 0.01 vs. HSA-native
20 nmol/mL; ˆ p < 0.001 vs. HSA-native 40 nmol/mL; # p < 0.001 vs. HSA-native 80 nmol/mL.
2.6. N-Acetylcysteine (NAC) Pre-Treatment Enhanced the Surface Thiols and Prevented Their
AOPP-Dependent Decrease
Following the observation that AOPP-modifi albumin induced thiol loss in the cell surface,
we pre-treated RAW264.7 cells with NAC before treating them with HSA-AOPP. NAC treatment
(0.1, 1, 2, and 5 mg/mL) dose-dependently increased surface thiols at all concentrations that were
used which ranged from 0.1 to 5 mg/mL (Figure 6A). Pre-treatment with NAC before HSA-AOPP
exposure starting from the 1 mg/mL concentration prevented the –SH group loss that was induced
by HSA-AOPP (Figure 6B). Moreover, AOPP-HSA induced exofacial thiol reduction, even in cells
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Figure 6. RAW264.7 cell surface thiols upon NAC treatment: (A) cells treated with increasing
concentrations of NAC; a d (B) lls pre-t eated with NAC and then treated with HSA-AOPP * p < 0.05
and § p < 0.01 vs. HSA-AOPP treatment.
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2.7. NAC Pre-Treatment Reduced ROS Production




Figure  7.  Intracellular  ROS  production.  Cells  pre‐treated  with  NAC  and  then  treated  with 
HSA‐AOPP. * p < 0.05, ** p < 0.01 and *** p < 0.001 vs. HSA‐AOPP treatment. 
2.8. The Effect of NAC Treatment on Cell Surface Markers 
Based on our  experimental observations with NAC  for  cell  surface  thiol  expression  and  for 
intracellular ROS production, the concentrations of 0.1 and 1 mg/mL NAC were used to quantify the 
expression of  specific DC surface markers. NAC at  the concentration of 1 mg/mL, but not at  the 
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Figure 8. Evaluation of cell surface dendritic markers CD40 (a); MHC Class II (b) and CD86 (c) in
RAW264.7 cells following NAC pre-treatment. * p < 0.05 vs. HSA-AOPP treatment.
2.9. Dendritic Cell Functional Assay. MLR for T-Cell Proliferation Induced by HSA-AOPP Treated
RAW264.7 Cells
RAW264.7 cells treated with HSA-AOPP for 48 h and then co-incubated with lymphocytes for
five days induced proliferative T-cell activity. NAC pretreatment of RAW264.7 cells abolished T cell
proliferation (Figure 9).
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Figure 10. Proliferative p38 PKinase (a) and J K (b) phosphorylation induced in RA cells by
S - PP. * p < 0.05 vs. tr; ** p < 0.01 vs. Ctr; § p < 0.05 vs. corresponding HSA-AOPP treatment.
2.11. Effects of N-Ethylmaleimide, a Thiol Modifier, on RAW264.7 Cell ROS Production and DC Markers
To further check the role of thiol groups as a mechanism for DC formation, we treated cells with
10 and 25 µM N-ethylmaleimide and we evaluated the effect on intracellular ROS production and
on the expression of the DC markers CD40 and MHC class II. N-ethylmaleimide strongly increased
ROS production when administered alone and strengthened the effect of HSA-AOPP. The free radical
inducer Ter-butyl-hydroperoxide (TBHP), that was used as a positive control, was also potentiated by
the treatment with N-ethylmaleimide (Figure 11A). The surface expression of CD40 and MHC class II
was increased by N-ethylmaleimide alone; the increase in DC markers induced by AOPP treatment
was also potentiated by the thiol modifier (Figure 11B,C).
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Figure 11. Effect of the thiol modifier N-ethylmaleimide on RAW264.7 cells: (A) intracellular ROS
production; and (B,C) surface expression of CD40 and MHC class II. * p < 0.05 vs. treatment without
HSA-AOPP; ** p < 0.01 vs. treatment without HSA-AOPP.
2.12. GSH and GSH/GSSG Ratio Decreased Following Treatment by HSA-AOPP in RAW264.7 Cells
RAW264.7 cells treated with HSA-AOPP for 2 h showed a decrease in glutathione levels and
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Figure 12. Glutathione (GSH) (a) and GSH/GSSG (b) evaluation in RAW264.7 cells. p < 0.05 vs. Ctr;
p < 0.05 vs. corresponding AOPP treated cells.
3. Discussion
Our results indicate that AOPP-albumin induces a transition toward DC phen type in cu tured
RAW264.7 macrophages. This process involves changes in intracellular ROS production and in
cell surface thiol groups. We have also shown that NAC supplementation in cultured RAW264.7
macrophages prevents intracellular ROS production and oxidation of plasma membrane thiols,
and blocks HSA-AOPP induced DC differentiation.
The biological relevance of the non-oncotic properties of albumin in blood plasma as a major
target for oxidative modifications, in particular for those induced by hypochlorous acid, has already
been reported [21,22]. Albumin in plasma has more potent free radical scavenger properties than low
molecular weight antioxidants like scorbic acid [23].
Oxidati n of albumin induces post-translational modifications that are collectively expressed as
AOPP, which not only represent an oxidative stress product a d biomarker, but also induce further
ROS production in cells as shown elsewhere and confirmed by our results, thus sustaining the existence
of a feedback loop [11]. It has been convincingly shown that an excess of oxidative stress is linked to,
and promotes, inflammation and immune cell activation.
AOPP act as uremic toxins on the kidney and other organs and their accumulation is an
independent risk factor for cardiovascular events especially but not exclusively in CKD. We previously
found that AOPP plasma levels were increased in cardiovascular diseases [24], as well as in
pro-at erogen c conditions [25].
Given its ability to circulate throughout th body, oxidized albumin acts as a systemic danger
signal and/or a damage-associated molecular pattern (DAMP) with immunogenic activity. Along this
line, high AOPP plasma levels may contribute to innate immunity dysregulation mediated by
an excessive DC differentiation and activation. Herein we provide proof that hypochlorite modified
proteins may be immunogenic not only because they are recognized by macrophages and DCs as
Biedron et al. previously described, but also because they stimulate and drive the differentiation of
DCs from macrophages [26].
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The complex role played by DCs at both the systemic and local level is dependent on, and finely
tuned by, their interaction and overlap with the circulating monocytes and with the macrophages in
tissues. As an example, macrophages displaying DC-like features are present in the kidney, but due
to the multiplicity of functions and distribution of these cells, at this time we are still far from a clear
understanding of their role in modulating or promoting rapid progression of renal damage [27,28].
Recent detection of DCs in atherosclerotic plaque, both in humans and in animal models, is
of the utmost interest, given the myriad functions of DCs, which include lipid uptake, antigen
presentation, efferocytosis, and inflammation resolution. In particular, CD40, MHC Class II and CD1d
DC marker expressions have been found in atherosclerotic lesions [29]. Increased DC differentiation
of mononuclear cells collected from patients with acute coronary syndromes point to a role of these
cells in specific cardiovascular diseases associated with systemic and local (coronary plaque lesion)
inflammatory activity [30].
As previously shown by Alderman et al., in vitro AOPP supplementation to DCs differentiated
from human monocytes treated with IL-4 and GMCSF increased their capacity to activate T cells,
but did not induce the expression of DC maturation markers [31].
We found that HSA-AOPP is able to induce a phenotypic transition from macrophages toward
cells with typical dendritic morphology. Surface DC markers were increased by AOPP treatment, as
proven by the expression of CD40 and of MHC class II which is known as a classical antigen-presenting
molecule. In addition, we showed the upregulation of co-stimulatory molecule CD86, which interacts
with its receptor CD28 on T cells and is needed for T cell stimulation. Furthermore, these DCs possessed
functional DC activity in stimulating the proliferation of T-lymphocytes. The trans-differentiation of
macrophages into DCs may represent a source of potent antigen-presenting dendritic cells. We believe
that these cells may trigger and drive a series of immune inflammatory reactions that could be
potentially detrimental to the vessel wall stability of the atherosclerotic plaque that is present in
patients with chronic renal damage.
Proteins located at the external cell membrane level face an extracellular oxidizing environment
and their thiols are mostly oxidized as disulfides. Moreover, the intracellular redox state also regulates
the external cell surface thiols, thus intra and extracellular thiols are tightly regulated and their
perturbation triggers signaling, leading to cell phenotypic and functional modifications [32,33].
There are several biological consequences related to reduced levels of plasma membrane cell
thiols. Their loss is associated with the induction of p38 MAP kinase cell signaling, leading to apoptosis
in vitro in U937 cells [34]. Moreover, Tanaka et al. found that 1-chloro-2,4-dinitrobenzene and diethyl
maleate, which oxidize thiol groups, inhibited the H2O2-induced phosphorylation of eNOS and
Akt [35]. Thiol redox status has been convincingly associated with progression of atherosclerosis [36].
Oxidation of plasma membrane thiols has been proposed as the trigger of an inflammatory mechanism
that leads to the onset and progression of atherosclerosis through H2O2 production, NF-kB activation,
enhanced expression of cell-cell adhesion molecules, and attachment of monocytes to endothelial
cells [37].
We found that the cell surface thiols dose-dependently decreased following HSA-AOPP treatment
of RAW264.7 macrophages, suggesting that the –SH group decrease on the cell surface may be part of
a signaling mechanism, that together with ROS production, results in the phenotypic modifications
of RAW macrophages toward a dendritic phenotype. On the other hand, treatment with NAC
recovered surface thiol loss, limited ROS production and hampered the macrophage to dendritic
phenotype transition.
NAC is used in patients with chronic bronchitis, as well as to fight liver damage after
acetaminophen poisoning, and to reduce renal damage associated with the use of contrast agent.
NAC also plays a role in the modulation of atherosclerotic processes; in experimental models of
damage to the arterial wall, NAC was effective in reducing both neointimal thickening promoted by
procoagulant activity and oxidative stress generated by balloon injury to normal abdominal aortae
and to aortae with neointima [38]. NAC supplementation to nitroglycerin reduced the occurrence of
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cardiovascular events in 200 patients with unstable angina who were followed-up for four months [39].
The main antioxidant NAC activities are represented by ROS scavenging and by participation in the
formation of GSH.
NAC has many possible mechanisms of action: besides being a free radical scavenger and a
substrate for GSH synthesis, it can interfere with thiol redox transition by reducing or limiting the
formation of disulfides. It is also likely that NAC treatment on cells acts by directly reducing the cell
membrane disulfides. NAC has been shown to keep exofacial surface protein thiols in their reduced
form; however, in our opinion, an inside-out activity cannot be excluded in our model, since NAC
easily enters cells.
It is known that in vivo the intracellular milieu is mainly reducing while the extracellular one
is mostly oxidizing, and several surface thiols are in the disulfide form. Thus, similarly, in vitro
cultured cells seem to have a considerable amount of membrane thiols in the disulfide oxidized form
that can be reduced by exogenous thiols from NAC. NAC also enters cells and may influence the
intracellular redox status, which in turn participates in the redox status of surface –SH. Therefore,
NAC may influence surface thiols both by acting as a regulator of intracellular redox status or as a
direct thiol-disulfide reductant at the external cell membrane level.
We found that NAC treatment dose-dependently increased the cell surface –SH groups. It can
be hypothesized that upon HSA-AOPP treatment, both the NAC rescue effects on the loss of plasma
membrane thiols and the inhibition of DC-like cell formation are at least partially mediated by NAC
thiol-disulfide exchange activity as a reductant. Furthermore, our observation of an initial CD36
increase within 24 h of treatment is consistent with the previous finding by Biedron et al. who suggested
that HSA-AOPP acts via its intake through receptors like CD36 or scavenger receptor SRA [26]. It is
known that CD36 is a mediator of AOPP damage through pro-oxidant stress dependent mechanisms in
different cell types [40]. Thus, we can hypothesize that CD36 may both uptake HSA-AOPP and drive
oxidative stress mediated activation of the cell, both of which lead to processing of oxidized albumin
and expression of DC markers. Since the receptor mediated mechanism may induce a response as a
consequence of HSA-AOPP binding, thereby eliciting downstream signaling, it is possible that NAC
also interferes with ROS activity at the intracellular level.
4. Conclusions
Our results highlight that uremic toxins such as plasma AOPP affect innate immune cell phenotype
and function by altering the thiol redox equilibrium. Even if DC content at the level of the kidney and
in atherosclerotic plaque appears to be negligible, macrophages at these sites are more abundant and
may migrate, accumulate and even proliferate in these inflammatory sites. We studied (in vitro) and
herein describe a new mechanism related to an excess of oxidized proteins that promotes an imbalance
in the thiol-redox equilibrium that might play a role in the rapid plaque progression observed in
patients with advanced kidney disease. As a next step, we should verify in humans with kidney
disease whether increased amounts of AOPP are associated with specific features of macrophages in
atherosclerotic plaque. At this time, we also believe that dissection of thiol redox signaling in innate
immune cells modulated by AOPP represents an important research topic which could help us to
identify new and more specific therapeutic strategies to be delivered to high-risk CKD patients with
coronary and extra-coronary atherosclerosis.
5. Materials and Methods
5.1. Materials
Potassium iodide (KI), chloramine-T, human serum albumin, sodium-hypochlorite,
N-ethylmaleimide and Citric acid monohydrate were purchased from Sigma-Aldrich (Milan, Italy)
and phosphate buffer saline (PBS buffer, 0.1 mol/L sodium phosphate, 0.15 mol/L sodium chloride,
pH 7.2) were bought from Euroclone.
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5.2. AOPP Preparation
Human serum albumin (30 mg/mL) was incubated with 100 mM HOCl at room temperature
for 30 min. The reaction was stopped by an equimolar concentration of thiosulfate to block excess
unreacted HOCl, after which extensive dialysis was carried out for 24 h at 4 ◦C.
5.3. AOPP Evaluation
AOPP in HSA preparations were evaluated according to the improved method of
Hanasand M et al. [41]. Briefly, 40 µL samples were pipetted into a 96-well microplate and 160 µL of
0.20 mol/L citric acid was added. A calibration curve of Chloramine-T standards prepared fresh daily
in 0.20 mol/L citric acid and KI (10 µL; 1.16 mol/L in PBS) was added to the standards. The absorbance
was read at 340 nm on a Thermo Labsystems Ascent IEMS microplate reader. AOPP concentrations
were expressed as nmol/mL of chloramine-T equivalents.
5.4. Cells and Treatments
The RAW264.7 macrophage cell line was from American Type Culture Collection (ATCC, Rockville,
MD, USA). In our HSA preparations, AOPP concentrations were 154.04 ± 12.3 nmol/mg of protein
in HOCl-treated HSA and 0.81 ± 0.2 nmol/mg in native HSA. In preliminary experiments, to mimic
a lower rate of oxidative stress, we oxidized HSA with 20 mM HOCl, which resulted in AOPP
concentration of 32.8 ± 5.2 nmol/mg of protein. The effects of the two AOPP preparations (32.8 ± 5.2
and 154.04 ± 12.3 nmol/mg of protein) on the expression of DC surface markers in RAW264.7 cells
are shown in Figure S1 in Supplementary material. Cells were treated in complete medium in 6, 12 or
24 wells (depending on the experimental determinations) with increasing AOPP-HSA concentrations
ranging from 1 to 80 nmoles/mL of AOPP, corresponding to AOPP levels found in plasma from normal
subjects and hemodialysis patients [1]. Native-HSA at concentrations corresponding to those used for
AOPP-HSA were also tested. Results are the mean of 3 to 5 experiments.
5.5. Flow Cytometry
To assess DC surface markers, cells were stained with antibodies for CD40, CD36, CD86 and
MHC (class II) from Life technologies. An Attune acoustic focusing cytometer with attune cytometric
software was used to analyze the samples. Exofacial thiols were assessed by AlexaFluor 488-maleimide
(Life Technologies, Waltham, MA, USA) staining for 30 min at 37 ◦C in PBS. For this staining,
RAW264.7 cells were treated with NAC for 30 min and then washed 3× with PBS and detached by
trypsin. Detached cells were centrifuged and resuspended in PBS containing AlexaFluor 488-maleimide
and stained for 30 min. After 2× washings, cells were analyzed on an Attune Acoustic Focusing
cytometer. Intracellular ROS production was evaluated by dichlorofluorescein diacetate (DCFH-DA,
Sigma-Aldrich, Milan, Italy). Following treatment cells were stained with 5 µM DCFH-DA in PBS for
20 min at 37 ◦C. Apoptosis was evaluated by flow cytometry using Alexa Fluor 488 Annexin V/Dead
Cell Apoptosis Kit (Life Technologies, Waltham, MA, USA).
5.6. Western Blotting
Cells were lysated in RIPA buffer and run on reducing SDS-acrylamide gels. Samples were
electrotransferred to PVDF, and the membranes were saturated at room temperature for 1 h, incubated
with primary antibodies overnight, and then with the corresponding horseradish peroxidase-secondary
antibodies (Santa Cruz, Heidelberg, Germany) for 1 h at room temperature. The bands were visualized
by ECL chemiluminescence (Pierce, Monza, Italy). Bands were quantified by optical densitometry.
5.7. Glutathione Evaluation
Glutathione (GSH and GSSG) was evaluated as described elsewhere [42]. After treatment, cells
were detached and harvested in a PBS solution and about 25% of the cell suspension was used for
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protein dosage, the remaining 75% of the cell suspension was mixed with the same volume of the
precipitating solution (2 mM EDTA, 0.61 N TCA and 0.02 N HCl) and centrifuged (Euroclone, Milan,
Italy) at 4000 rpm for 15 min. at 4 ◦C. The resulting supernatant was used to evaluate the GSH and
GSSG contents by the reaction with o-phthalaldehyde (OPA). Standard solutions were prepared by
dissolving GSH or GSSG in Redox Quenching Buffer (RQB) containing 20 mM HCl, 5 mM DTPA
and 10 mM ascorbic acid. Samples or standards (GSH or GSSG) were treated with 5% TCA-RQB
solution. To evaluate GSSG levels, N-ethylmaleimide (7.5 mM in RQB) was added. Subsequently, 1 M
potassium phosphate (KPi) buffer (pH 7.0) was added to all tubes and the samples were incubated for
5 min. at room temperature. For the GSSG assay, 100 mM dithionite-RQB was used and the samples
were incubated for 60 min. at room temperature following which 0.1 M KPi buffer (pH 6.9) and
OPA (5 mg/mL in methanol) were added. After a 30-min incubation at room temperature, sample
fluorescence was monitored by a Perkin Elmer fluorimeter (Perkin Elmer Life and Analytical Sciences,
Shelton, CT, USA) at 365/430 nm.
5.8. Mixed Leukocyte Reactions (MLRs)
For the MLRs utilizing mouse cells, 2 × 105 CFSE (2 µM)-labeled allogeneic (BL6) lymphocytes
CD4+ cells (responders) were cultured with RAW264.7 cells (stimulators) treated or not with
HSA-AOPP. Cells were plated in microplates (Corning, NY, USA) at S:R ratios of 1:5, 1:10 and 1:100.
Proliferation of alive (propidium-iodide negative) CD3+CD4+ cells was evaluated by flow cytometry
as CFSE dilution after a 5-day incubation.
5.9. Statistical Analysis
Data were expressed as mean ± SE. Differences between means were compared by Student’s
t test. A p < 0.05 was considered statistically significant.
Supplementary Materials: The following are available online at www.mdpi.com/2072-6651/9/1/27/s1,
Figure S1: Effects of AOPP concentration of 32.8 ± 5.2 and 154.04 ± 12.3 (nmol/mg of protein) on the expression
of DC surface markers. * p < 0.05 vs. Ctr; ** p < 0.01 vs. Ctr.
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